Drug profile · INN
azilsartan kamedoxomil
AZILSARTAN MEDOXOMIL AND CHLORTHALIDONE
azilsartan kamedoxomil (AZILSARTAN MEDOXOMIL AND CHLORTHALIDONE) is a type-1 angiotensin ii receptor antagonist. Route of administration: oral. Current US regulatory status: approved.
Drug details — azilsartan kamedoxomil
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 3
- Programs
- 17
- Data quality
- 0.84
Quick answer
azilsartan kamedoxomil (AZILSARTAN MEDOXOMIL AND CHLORTHALIDONE) is a type-1 angiotensin ii receptor antagonist. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Type-1 angiotensin II receptor antagonist
Primary target: Type-1 angiotensin II receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is azilsartan kamedoxomil?
azilsartan kamedoxomil (AZILSARTAN MEDOXOMIL AND CHLORTHALIDONE) is a type-1 angiotensin ii receptor antagonist. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for azilsartan kamedoxomil?
AZILSARTAN MEDOXOMIL AND CHLORTHALIDONE is a marketed brand name for azilsartan kamedoxomil. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of azilsartan kamedoxomil?
azilsartan kamedoxomil has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.